SlideShare a Scribd company logo
ARGUS
PATIENT SCREEN
01/29/17
Katalyst Healthcares & Life Sciences
1
Patient Information:
For SR & LIT cases
 Enter initials only
 Protect Confidentiality box not checked
01/29/17Katalyst Healthcares & Life Sciences
2
Patient Information
For PMS cases
 Enter initials only
 Enter patient ID if reported
 Protect Confidentiality box not checked
01/29/17Katalyst Healthcares & Life Sciences
3
Patient Information (cont)Patient Information (cont)
 Enter date of birth. If incomplete type in hyphen for missing
information. eg ‘-’ ‘-’ 1994
 Patient age:
Age and age group will only be calculated automatically if the
date of birth and a full event onset date are entered.
 If partial onset date has been entered enter the age and age
group manually.
 Ethnicity: SR - To be entered as locally required
CT - Entered if information provided
01/29/17Katalyst Healthcares & Life Sciences
4
Other Relevant History:Other Relevant History:
 Enter relevant medical history including current medical
conditions.
 As a general rule, indications of suspect drugs should not be
entered as relevant history. However there are exceptions
where the condition has happened more than once eg.
Transplant.
 The indications of co-medications should be entered and
coded in the relevant medical history field as they highlight
the current condition of the patient.
01/29/17Katalyst Healthcares & Life Sciences
5
Other Relevant History (Cont)Other Relevant History (Cont)
 The following ‘Condition Type’ are used by Novartis:
- Current Condition
- Historical Condition
- Historical Drug
- Drug Reaction History
- Family History
Leave blank if unknown
 Repeat ‘Description’ verbatim term in the Notes field if the Preferred
Term is not specific enough.
01/29/17Katalyst Healthcares & Life Sciences
6
Medical History Field
 Historical drugs can be represented in the medical history
field if required.
 Select ‘Historical Drug’ as condition type.
 The drug name can then be coded against the WHO
dictionary.
 The Indication for the ‘Historical Drug’ can be entered as
well as the reaction if known
01/29/17Katalyst Healthcares & Life Sciences
7
‘Historical Drugs’ Condition type
When to Use:
 This condition should be used only in the following
situations:
− Historical drugs that have been highlighted by the reporter as
medically relevant to the patient’s status.
− Specific historical drugs/therapies highlighted by the Novartis
medical safety physician as medically relevant and requiring
routine screening.
01/29/17Katalyst Healthcares & Life Sciences
8
Definition of a historical drug:
 The decision as to whether a medication is historical
or not should be based on the following:
− If unlikely that the product is still in the body system and there are
no biological effects known or suspected in the patient, enter as a
‘Historical Drug’ in the Other Relevant History.
− If the drug is still in the body system and there is a suggestion of
biological activity (even if the kinetics suggest complete
elimination), the product should be entered as a co-medication in
the Product tab
− If in doubt, consult the PVL.
‘Historical Drugs’ Condition type
01/29/17Katalyst Healthcares & Life Sciences
9
Other Relevant History (Cont)Other Relevant History (Cont)
 To enter more patient history data click on the Add button
 To delete a history record, click on the Delete button
 Ongoing checkbox: Not used by Novartis
01/29/17Katalyst Healthcares & Life Sciences
10
Laboratory Data:
 Relevant tests such as laboratory data, scans, tests
and examinations should be captured in the
coded field for E2b submissions and also as free
texts in the free text Relevant Tests field
01/29/17Katalyst Healthcares & Life Sciences
11
Coded Lab Data Field:
 Only enter test results that are relevant to the events being
reported. The coded field should summarise the essential test results
and should only include tests which:
 Show abnormalities outside of the normal range relevant to the events being
reported.
 Disprove a diagnosis or suspected underlying cause for the event
 Support or confirm a diagnosis
 Show trends, e.g. increasing white blood cell count during an infection. Always
include a baseline value if provided followed by the peak and resolution values
 Show a normalisation of previously abnormal test results
 Do not include tests which:
 Show abnormal values that are normal/baseline in the specific patient population
under study.
 Are not relevant to the events being reported.
01/29/17Katalyst Healthcares & Life Sciences
12
Coded Lab Data Field:
 Type in the test name as reported
and click on ‚Encode‘
 Click on units field and select the
appropriate units if reported
 Enter the Normal range if reported
 To enter a test result and
click on ‚Add test‘
01/29/17
Katalyst Healthcares & Life Sciences
13
Coded Lab Data Field:
 Click on ‚Add Date‘
 Enter the date and click
on the orange triangle
and click on Add
01/29/17 Katalyst Healthcares & Life Sciences
14
Coded Lab Data Field:
 Enter the result and select
Normal, High or low from
the drop down list
 The Notes field can also be used
to display results for investigations
which do not have numerical
values e.g. ECG and biopsy results.
01/29/17Katalyst Healthcares & Life Sciences
15
Relevant Test Field:
 In the event that a test can not be coded or captured appropriately in the
coded text field, it can be entered as free text in the relevant test field.
 Enter date or relevant time point of test in brackets, e.g. (14 Mar 2007) or (10
days post transplant) or (Date unknown)
 Enter test specification followed by test result, e.g. Haemoglobin 9.4
 Enter test units if reported, e.g. Haemoglobin 9.4 g/dL
 If the same test is repeated over a number of days, a normal range should only
be entered next to the first entry as shown in the example.
 Group similar laboratory tests. Abbreviations can be used if the test is fully
defined for the first result or in the case narrative.
 Enter repeated tests in date order so that any trend over time can be clearly
seen
 Example:
(Date unknown) AST 20 U/L (normal range 15-30)
(Date unknown) AST 150 U/L
(Date unknown) AST 40 U/L
01/29/17Katalyst Healthcares & Life Sciences
16
Thank YouThank You
&&
QuestionsQuestions
17
Contact:
Katalyst Healthcare’s & Life Sciences
South Plainfield, NJ, USA 07080.
E-Mail: info@KatalystHLS.com

More Related Content

What's hot

Aggregate Reporting_Pharmacovigilance_Katalyst HLS
Aggregate Reporting_Pharmacovigilance_Katalyst HLSAggregate Reporting_Pharmacovigilance_Katalyst HLS
Aggregate Reporting_Pharmacovigilance_Katalyst HLS
Katalyst HLS
 
Collection, Processing and Reporting of ICSR
Collection, Processing and Reporting of ICSRCollection, Processing and Reporting of ICSR
Collection, Processing and Reporting of ICSR
ClinosolIndia
 
Guideline on good pharmacovigilance practices ( gvp)
Guideline on good pharmacovigilance practices ( gvp)Guideline on good pharmacovigilance practices ( gvp)
Guideline on good pharmacovigilance practices ( gvp)
Nahla Amin
 
Pharmacovigilance regulations as per European Union
Pharmacovigilance regulations as per European UnionPharmacovigilance regulations as per European Union
Pharmacovigilance regulations as per European Union
Bindu Kshtriya
 
PMS (post marketing surveillance)
PMS (post marketing surveillance)PMS (post marketing surveillance)
PMS (post marketing surveillance)
SANDEEP LOHMOR
 
ICSR (individual case safety report)
ICSR (individual case safety report)ICSR (individual case safety report)
ICSR (individual case safety report)
ClinosolIndia
 
Post marketing surveillance
Post marketing surveillancePost marketing surveillance
Post marketing surveillance
suraj mungase
 
USFDA NDA Vs BLA
USFDA NDA Vs BLAUSFDA NDA Vs BLA
USFDA NDA Vs BLA
Girish Swami
 
Pharmacovigilance Process Work Flow - Katalyst HLS
Pharmacovigilance Process Work Flow - Katalyst HLSPharmacovigilance Process Work Flow - Katalyst HLS
Pharmacovigilance Process Work Flow - Katalyst HLS
Katalyst HLS
 
Patient narrative preparation by barka binmazi
Patient narrative preparation by barka binmaziPatient narrative preparation by barka binmazi
Patient narrative preparation by barka binmazi
Barka Binmazi
 
Development safety update report (dsur) pharmacovigilance and safety
Development safety update report (dsur)   pharmacovigilance and safetyDevelopment safety update report (dsur)   pharmacovigilance and safety
Development safety update report (dsur) pharmacovigilance and safety
Azierta
 
ICSR Narrative Writing_Katalyst HLS
ICSR Narrative Writing_Katalyst HLSICSR Narrative Writing_Katalyst HLS
ICSR Narrative Writing_Katalyst HLS
Katalyst HLS
 
Literature monitoring for pv what are we doing at galderma elsevier webinar
Literature monitoring for pv   what are we doing at galderma elsevier webinarLiterature monitoring for pv   what are we doing at galderma elsevier webinar
Literature monitoring for pv what are we doing at galderma elsevier webinar
Ann-Marie Roche
 
DSUR
DSURDSUR
ICH - E2D Pharmacovigilance and Drug Safety - Professor Peivand Pirouzi
ICH - E2D Pharmacovigilance and Drug Safety - Professor Peivand PirouziICH - E2D Pharmacovigilance and Drug Safety - Professor Peivand Pirouzi
ICH - E2D Pharmacovigilance and Drug Safety - Professor Peivand Pirouzi
Pharmaceutical Compliance Inspection unit, Crown College of Canada
 
Essential document (ich gcp)
Essential document (ich gcp)Essential document (ich gcp)
Essential document (ich gcp)bhunjawa
 
AN OVERVIEW AND IMPORTANCE OF PHARMACOVIGILANCE
AN OVERVIEW AND IMPORTANCE OF PHARMACOVIGILANCEAN OVERVIEW AND IMPORTANCE OF PHARMACOVIGILANCE
AN OVERVIEW AND IMPORTANCE OF PHARMACOVIGILANCE
Ramakrishna K
 
Case Processing Work Flow in Pharmacoviglance
Case Processing Work Flow in PharmacoviglanceCase Processing Work Flow in Pharmacoviglance
Case Processing Work Flow in Pharmacoviglance
ClinosolIndia
 

What's hot (20)

Aggregate Reporting_Pharmacovigilance_Katalyst HLS
Aggregate Reporting_Pharmacovigilance_Katalyst HLSAggregate Reporting_Pharmacovigilance_Katalyst HLS
Aggregate Reporting_Pharmacovigilance_Katalyst HLS
 
clinical research
clinical researchclinical research
clinical research
 
Collection, Processing and Reporting of ICSR
Collection, Processing and Reporting of ICSRCollection, Processing and Reporting of ICSR
Collection, Processing and Reporting of ICSR
 
Guideline on good pharmacovigilance practices ( gvp)
Guideline on good pharmacovigilance practices ( gvp)Guideline on good pharmacovigilance practices ( gvp)
Guideline on good pharmacovigilance practices ( gvp)
 
Pharmacovigilance regulations as per European Union
Pharmacovigilance regulations as per European UnionPharmacovigilance regulations as per European Union
Pharmacovigilance regulations as per European Union
 
PMS (post marketing surveillance)
PMS (post marketing surveillance)PMS (post marketing surveillance)
PMS (post marketing surveillance)
 
Med dra Basics
Med dra  BasicsMed dra  Basics
Med dra Basics
 
ICSR (individual case safety report)
ICSR (individual case safety report)ICSR (individual case safety report)
ICSR (individual case safety report)
 
Post marketing surveillance
Post marketing surveillancePost marketing surveillance
Post marketing surveillance
 
USFDA NDA Vs BLA
USFDA NDA Vs BLAUSFDA NDA Vs BLA
USFDA NDA Vs BLA
 
Pharmacovigilance Process Work Flow - Katalyst HLS
Pharmacovigilance Process Work Flow - Katalyst HLSPharmacovigilance Process Work Flow - Katalyst HLS
Pharmacovigilance Process Work Flow - Katalyst HLS
 
Patient narrative preparation by barka binmazi
Patient narrative preparation by barka binmaziPatient narrative preparation by barka binmazi
Patient narrative preparation by barka binmazi
 
Development safety update report (dsur) pharmacovigilance and safety
Development safety update report (dsur)   pharmacovigilance and safetyDevelopment safety update report (dsur)   pharmacovigilance and safety
Development safety update report (dsur) pharmacovigilance and safety
 
ICSR Narrative Writing_Katalyst HLS
ICSR Narrative Writing_Katalyst HLSICSR Narrative Writing_Katalyst HLS
ICSR Narrative Writing_Katalyst HLS
 
Literature monitoring for pv what are we doing at galderma elsevier webinar
Literature monitoring for pv   what are we doing at galderma elsevier webinarLiterature monitoring for pv   what are we doing at galderma elsevier webinar
Literature monitoring for pv what are we doing at galderma elsevier webinar
 
DSUR
DSURDSUR
DSUR
 
ICH - E2D Pharmacovigilance and Drug Safety - Professor Peivand Pirouzi
ICH - E2D Pharmacovigilance and Drug Safety - Professor Peivand PirouziICH - E2D Pharmacovigilance and Drug Safety - Professor Peivand Pirouzi
ICH - E2D Pharmacovigilance and Drug Safety - Professor Peivand Pirouzi
 
Essential document (ich gcp)
Essential document (ich gcp)Essential document (ich gcp)
Essential document (ich gcp)
 
AN OVERVIEW AND IMPORTANCE OF PHARMACOVIGILANCE
AN OVERVIEW AND IMPORTANCE OF PHARMACOVIGILANCEAN OVERVIEW AND IMPORTANCE OF PHARMACOVIGILANCE
AN OVERVIEW AND IMPORTANCE OF PHARMACOVIGILANCE
 
Case Processing Work Flow in Pharmacoviglance
Case Processing Work Flow in PharmacoviglanceCase Processing Work Flow in Pharmacoviglance
Case Processing Work Flow in Pharmacoviglance
 

Similar to Argus Patient Screen Tab Training - Katalyst HLS

Pneumonia Of Left Lung Essay.docx
Pneumonia Of Left Lung Essay.docxPneumonia Of Left Lung Essay.docx
Pneumonia Of Left Lung Essay.docx
sdfghj21
 
icsrnarrativewritingkatalysthls-170224043430.pdf
icsrnarrativewritingkatalysthls-170224043430.pdficsrnarrativewritingkatalysthls-170224043430.pdf
icsrnarrativewritingkatalysthls-170224043430.pdf
dabloosaha
 
For this assignment, you are to complete aclinical case - narr.docx
For this assignment, you are to complete aclinical case - narr.docxFor this assignment, you are to complete aclinical case - narr.docx
For this assignment, you are to complete aclinical case - narr.docx
sleeperharwell
 
Readmission of Diabetes Patients Report
Readmission of Diabetes Patients ReportReadmission of Diabetes Patients Report
Readmission of Diabetes Patients ReportHong Lu
 
For this assignment, you are to complete aclinical case - narrat.docx
For this assignment, you are to complete aclinical case - narrat.docxFor this assignment, you are to complete aclinical case - narrat.docx
For this assignment, you are to complete aclinical case - narrat.docx
sleeperharwell
 
Guidelines for Achieving a Compliant Query Practice (2016 Update).docx
Guidelines for Achieving a Compliant Query Practice (2016 Update).docxGuidelines for Achieving a Compliant Query Practice (2016 Update).docx
Guidelines for Achieving a Compliant Query Practice (2016 Update).docx
whittemorelucilla
 
Treatment passport
Treatment passportTreatment passport
Treatment passport
ITPCMENA
 
For this weeks discussion, we will be looking at local or nationa
For this weeks discussion, we will be looking at local or nationaFor this weeks discussion, we will be looking at local or nationa
For this weeks discussion, we will be looking at local or nationa
ShainaBoling829
 
Laboratory Medicine Curriculum
Laboratory Medicine Curriculum Laboratory Medicine Curriculum
Laboratory Medicine Curriculum
mazen khaled
 
All about Clinical Trials_Katalyst HLS
All about Clinical Trials_Katalyst HLSAll about Clinical Trials_Katalyst HLS
All about Clinical Trials_Katalyst HLS
Katalyst HLS
 
How to recognize ADRs in patients.@ Clinical Pharmacy
How to recognize ADRs in patients.@ Clinical PharmacyHow to recognize ADRs in patients.@ Clinical Pharmacy
How to recognize ADRs in patients.@ Clinical Pharmacy
Drpradeepthi
 
008473_pre-anesthesia-evaluation-guidelines_v7_160425.pdf
008473_pre-anesthesia-evaluation-guidelines_v7_160425.pdf008473_pre-anesthesia-evaluation-guidelines_v7_160425.pdf
008473_pre-anesthesia-evaluation-guidelines_v7_160425.pdf
NasrullahKhan94
 
E&M
E&ME&M
E&Myury
 
Statistics-in-Drug-Development-2015-UC-BS.pptx
Statistics-in-Drug-Development-2015-UC-BS.pptxStatistics-in-Drug-Development-2015-UC-BS.pptx
Statistics-in-Drug-Development-2015-UC-BS.pptx
DiptoKumerSarker1
 
Impd dossier
Impd dossierImpd dossier
Impd dossier
Prakash Ata
 
Pharmacovigilance Overview
Pharmacovigilance OverviewPharmacovigilance Overview
Pharmacovigilance Overview
SivasankaranV
 
APA Title page, running head, page numbers, reference sheet. Use L.docx
APA Title page, running head, page numbers, reference sheet. Use L.docxAPA Title page, running head, page numbers, reference sheet. Use L.docx
APA Title page, running head, page numbers, reference sheet. Use L.docx
justine1simpson78276
 
Adverse Events and Serious Adverse Events - Katalyst HLS
Adverse Events and Serious Adverse Events - Katalyst HLSAdverse Events and Serious Adverse Events - Katalyst HLS
Adverse Events and Serious Adverse Events - Katalyst HLS
Katalyst HLS
 
EMR as a highly powerful European RWD source
EMR as a highly powerful European RWD sourceEMR as a highly powerful European RWD source
EMR as a highly powerful European RWD source
IMSHealthRWES
 

Similar to Argus Patient Screen Tab Training - Katalyst HLS (20)

Pneumonia Of Left Lung Essay.docx
Pneumonia Of Left Lung Essay.docxPneumonia Of Left Lung Essay.docx
Pneumonia Of Left Lung Essay.docx
 
icsrnarrativewritingkatalysthls-170224043430.pdf
icsrnarrativewritingkatalysthls-170224043430.pdficsrnarrativewritingkatalysthls-170224043430.pdf
icsrnarrativewritingkatalysthls-170224043430.pdf
 
For this assignment, you are to complete aclinical case - narr.docx
For this assignment, you are to complete aclinical case - narr.docxFor this assignment, you are to complete aclinical case - narr.docx
For this assignment, you are to complete aclinical case - narr.docx
 
Readmission of Diabetes Patients Report
Readmission of Diabetes Patients ReportReadmission of Diabetes Patients Report
Readmission of Diabetes Patients Report
 
For this assignment, you are to complete aclinical case - narrat.docx
For this assignment, you are to complete aclinical case - narrat.docxFor this assignment, you are to complete aclinical case - narrat.docx
For this assignment, you are to complete aclinical case - narrat.docx
 
Guidelines for Achieving a Compliant Query Practice (2016 Update).docx
Guidelines for Achieving a Compliant Query Practice (2016 Update).docxGuidelines for Achieving a Compliant Query Practice (2016 Update).docx
Guidelines for Achieving a Compliant Query Practice (2016 Update).docx
 
Treatment passport
Treatment passportTreatment passport
Treatment passport
 
For this weeks discussion, we will be looking at local or nationa
For this weeks discussion, we will be looking at local or nationaFor this weeks discussion, we will be looking at local or nationa
For this weeks discussion, we will be looking at local or nationa
 
Laboratory Medicine Curriculum
Laboratory Medicine Curriculum Laboratory Medicine Curriculum
Laboratory Medicine Curriculum
 
All about Clinical Trials_Katalyst HLS
All about Clinical Trials_Katalyst HLSAll about Clinical Trials_Katalyst HLS
All about Clinical Trials_Katalyst HLS
 
How to recognize ADRs in patients.@ Clinical Pharmacy
How to recognize ADRs in patients.@ Clinical PharmacyHow to recognize ADRs in patients.@ Clinical Pharmacy
How to recognize ADRs in patients.@ Clinical Pharmacy
 
008473_pre-anesthesia-evaluation-guidelines_v7_160425.pdf
008473_pre-anesthesia-evaluation-guidelines_v7_160425.pdf008473_pre-anesthesia-evaluation-guidelines_v7_160425.pdf
008473_pre-anesthesia-evaluation-guidelines_v7_160425.pdf
 
E&M
E&ME&M
E&M
 
Statistics-in-Drug-Development-2015-UC-BS.pptx
Statistics-in-Drug-Development-2015-UC-BS.pptxStatistics-in-Drug-Development-2015-UC-BS.pptx
Statistics-in-Drug-Development-2015-UC-BS.pptx
 
Impd dossier
Impd dossierImpd dossier
Impd dossier
 
Pharmacovigilance Overview
Pharmacovigilance OverviewPharmacovigilance Overview
Pharmacovigilance Overview
 
APA Title page, running head, page numbers, reference sheet. Use L.docx
APA Title page, running head, page numbers, reference sheet. Use L.docxAPA Title page, running head, page numbers, reference sheet. Use L.docx
APA Title page, running head, page numbers, reference sheet. Use L.docx
 
London 21.11.2008
London 21.11.2008London 21.11.2008
London 21.11.2008
 
Adverse Events and Serious Adverse Events - Katalyst HLS
Adverse Events and Serious Adverse Events - Katalyst HLSAdverse Events and Serious Adverse Events - Katalyst HLS
Adverse Events and Serious Adverse Events - Katalyst HLS
 
EMR as a highly powerful European RWD source
EMR as a highly powerful European RWD sourceEMR as a highly powerful European RWD source
EMR as a highly powerful European RWD source
 

More from Katalyst HLS

Risk Based Approach CSV Training_Katalyst HLS
Risk Based Approach CSV Training_Katalyst HLSRisk Based Approach CSV Training_Katalyst HLS
Risk Based Approach CSV Training_Katalyst HLS
Katalyst HLS
 
21 CFR Part11_CSV Training_Katalyst HLS
21 CFR Part11_CSV Training_Katalyst HLS21 CFR Part11_CSV Training_Katalyst HLS
21 CFR Part11_CSV Training_Katalyst HLS
Katalyst HLS
 
Study Setup_Katalyst HLS
Study Setup_Katalyst HLSStudy Setup_Katalyst HLS
Study Setup_Katalyst HLS
Katalyst HLS
 
Safety_Data_Reconciliation_Katalyst HLS
Safety_Data_Reconciliation_Katalyst HLSSafety_Data_Reconciliation_Katalyst HLS
Safety_Data_Reconciliation_Katalyst HLS
Katalyst HLS
 
Reports & Analysis_Katalyst HLS
Reports & Analysis_Katalyst HLSReports & Analysis_Katalyst HLS
Reports & Analysis_Katalyst HLS
Katalyst HLS
 
Protocol Understanding_Katalyst HLS
Protocol Understanding_Katalyst HLSProtocol Understanding_Katalyst HLS
Protocol Understanding_Katalyst HLS
Katalyst HLS
 
Oracle Study Setup_Katalyst HLS
Oracle Study Setup_Katalyst HLSOracle Study Setup_Katalyst HLS
Oracle Study Setup_Katalyst HLS
Katalyst HLS
 
Oracle Clinical Overview_Katalyst HLS
Oracle Clinical Overview_Katalyst HLSOracle Clinical Overview_Katalyst HLS
Oracle Clinical Overview_Katalyst HLS
Katalyst HLS
 
OCRDC Graphical Layout Features_Katalyst HLS
OCRDC Graphical Layout Features_Katalyst HLSOCRDC Graphical Layout Features_Katalyst HLS
OCRDC Graphical Layout Features_Katalyst HLS
Katalyst HLS
 
OC Procedure Progarmming Module_Katalyst HLS
OC Procedure Progarmming Module_Katalyst HLSOC Procedure Progarmming Module_Katalyst HLS
OC Procedure Progarmming Module_Katalyst HLS
Katalyst HLS
 
OC Backend_Katalyst HLS
OC Backend_Katalyst HLSOC Backend_Katalyst HLS
OC Backend_Katalyst HLS
Katalyst HLS
 
Mock CRF Design_Katalyst HLS
Mock CRF Design_Katalyst HLSMock CRF Design_Katalyst HLS
Mock CRF Design_Katalyst HLS
Katalyst HLS
 
Medical Coding_Katalyst HLS
Medical Coding_Katalyst HLSMedical Coding_Katalyst HLS
Medical Coding_Katalyst HLS
Katalyst HLS
 
Labs Module_Katalyst HLS
Labs Module_Katalyst HLSLabs Module_Katalyst HLS
Labs Module_Katalyst HLS
Katalyst HLS
 
Handling Third Party Vendor Data_Katalyst HLS
Handling Third Party Vendor Data_Katalyst HLSHandling Third Party Vendor Data_Katalyst HLS
Handling Third Party Vendor Data_Katalyst HLS
Katalyst HLS
 
Discrepany Management_Katalyst HLS
Discrepany Management_Katalyst HLSDiscrepany Management_Katalyst HLS
Discrepany Management_Katalyst HLS
Katalyst HLS
 
Discovery of Drug and Introduction to Clinical Trial__Katalyst HLS
Discovery of Drug and Introduction to Clinical Trial__Katalyst HLSDiscovery of Drug and Introduction to Clinical Trial__Katalyst HLS
Discovery of Drug and Introduction to Clinical Trial__Katalyst HLS
Katalyst HLS
 
Database Lock _ Unlock Procedure_Katalyst HLS
Database Lock _ Unlock Procedure_Katalyst HLSDatabase Lock _ Unlock Procedure_Katalyst HLS
Database Lock _ Unlock Procedure_Katalyst HLS
Katalyst HLS
 
Data Management Plan_Katalyst HLS
Data Management Plan_Katalyst HLSData Management Plan_Katalyst HLS
Data Management Plan_Katalyst HLS
Katalyst HLS
 
Data Loading and Data Entry_Katalyst HLS
Data Loading and Data Entry_Katalyst HLSData Loading and Data Entry_Katalyst HLS
Data Loading and Data Entry_Katalyst HLS
Katalyst HLS
 

More from Katalyst HLS (20)

Risk Based Approach CSV Training_Katalyst HLS
Risk Based Approach CSV Training_Katalyst HLSRisk Based Approach CSV Training_Katalyst HLS
Risk Based Approach CSV Training_Katalyst HLS
 
21 CFR Part11_CSV Training_Katalyst HLS
21 CFR Part11_CSV Training_Katalyst HLS21 CFR Part11_CSV Training_Katalyst HLS
21 CFR Part11_CSV Training_Katalyst HLS
 
Study Setup_Katalyst HLS
Study Setup_Katalyst HLSStudy Setup_Katalyst HLS
Study Setup_Katalyst HLS
 
Safety_Data_Reconciliation_Katalyst HLS
Safety_Data_Reconciliation_Katalyst HLSSafety_Data_Reconciliation_Katalyst HLS
Safety_Data_Reconciliation_Katalyst HLS
 
Reports & Analysis_Katalyst HLS
Reports & Analysis_Katalyst HLSReports & Analysis_Katalyst HLS
Reports & Analysis_Katalyst HLS
 
Protocol Understanding_Katalyst HLS
Protocol Understanding_Katalyst HLSProtocol Understanding_Katalyst HLS
Protocol Understanding_Katalyst HLS
 
Oracle Study Setup_Katalyst HLS
Oracle Study Setup_Katalyst HLSOracle Study Setup_Katalyst HLS
Oracle Study Setup_Katalyst HLS
 
Oracle Clinical Overview_Katalyst HLS
Oracle Clinical Overview_Katalyst HLSOracle Clinical Overview_Katalyst HLS
Oracle Clinical Overview_Katalyst HLS
 
OCRDC Graphical Layout Features_Katalyst HLS
OCRDC Graphical Layout Features_Katalyst HLSOCRDC Graphical Layout Features_Katalyst HLS
OCRDC Graphical Layout Features_Katalyst HLS
 
OC Procedure Progarmming Module_Katalyst HLS
OC Procedure Progarmming Module_Katalyst HLSOC Procedure Progarmming Module_Katalyst HLS
OC Procedure Progarmming Module_Katalyst HLS
 
OC Backend_Katalyst HLS
OC Backend_Katalyst HLSOC Backend_Katalyst HLS
OC Backend_Katalyst HLS
 
Mock CRF Design_Katalyst HLS
Mock CRF Design_Katalyst HLSMock CRF Design_Katalyst HLS
Mock CRF Design_Katalyst HLS
 
Medical Coding_Katalyst HLS
Medical Coding_Katalyst HLSMedical Coding_Katalyst HLS
Medical Coding_Katalyst HLS
 
Labs Module_Katalyst HLS
Labs Module_Katalyst HLSLabs Module_Katalyst HLS
Labs Module_Katalyst HLS
 
Handling Third Party Vendor Data_Katalyst HLS
Handling Third Party Vendor Data_Katalyst HLSHandling Third Party Vendor Data_Katalyst HLS
Handling Third Party Vendor Data_Katalyst HLS
 
Discrepany Management_Katalyst HLS
Discrepany Management_Katalyst HLSDiscrepany Management_Katalyst HLS
Discrepany Management_Katalyst HLS
 
Discovery of Drug and Introduction to Clinical Trial__Katalyst HLS
Discovery of Drug and Introduction to Clinical Trial__Katalyst HLSDiscovery of Drug and Introduction to Clinical Trial__Katalyst HLS
Discovery of Drug and Introduction to Clinical Trial__Katalyst HLS
 
Database Lock _ Unlock Procedure_Katalyst HLS
Database Lock _ Unlock Procedure_Katalyst HLSDatabase Lock _ Unlock Procedure_Katalyst HLS
Database Lock _ Unlock Procedure_Katalyst HLS
 
Data Management Plan_Katalyst HLS
Data Management Plan_Katalyst HLSData Management Plan_Katalyst HLS
Data Management Plan_Katalyst HLS
 
Data Loading and Data Entry_Katalyst HLS
Data Loading and Data Entry_Katalyst HLSData Loading and Data Entry_Katalyst HLS
Data Loading and Data Entry_Katalyst HLS
 

Recently uploaded

Dehradun #ℂall #gIRLS Oyo Hotel 9719300533 #ℂall #gIRL in Dehradun
Dehradun #ℂall #gIRLS Oyo Hotel 9719300533 #ℂall #gIRL in DehradunDehradun #ℂall #gIRLS Oyo Hotel 9719300533 #ℂall #gIRL in Dehradun
Dehradun #ℂall #gIRLS Oyo Hotel 9719300533 #ℂall #gIRL in Dehradun
chandankumarsmartiso
 
Colonic and anorectal physiology with surgical implications
Colonic and anorectal physiology with surgical implicationsColonic and anorectal physiology with surgical implications
Colonic and anorectal physiology with surgical implications
Dr Maria Tamanna
 
Basavarajeeyam - Ayurvedic heritage book of Andhra pradesh
Basavarajeeyam - Ayurvedic heritage book of Andhra pradeshBasavarajeeyam - Ayurvedic heritage book of Andhra pradesh
Basavarajeeyam - Ayurvedic heritage book of Andhra pradesh
Dr. Madduru Muni Haritha
 
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Oleg Kshivets
 
Top 10 Best Ayurvedic Kidney Stone Syrups in India
Top 10 Best Ayurvedic Kidney Stone Syrups in IndiaTop 10 Best Ayurvedic Kidney Stone Syrups in India
Top 10 Best Ayurvedic Kidney Stone Syrups in India
SwastikAyurveda
 
Pharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptx
Pharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptxPharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptx
Pharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptx
Dr. Rabia Inam Gandapore
 
Evaluation of antidepressant activity of clitoris ternatea in animals
Evaluation of antidepressant activity of clitoris ternatea in animalsEvaluation of antidepressant activity of clitoris ternatea in animals
Evaluation of antidepressant activity of clitoris ternatea in animals
Shweta
 
BRACHYTHERAPY OVERVIEW AND APPLICATORS
BRACHYTHERAPY OVERVIEW  AND  APPLICATORSBRACHYTHERAPY OVERVIEW  AND  APPLICATORS
BRACHYTHERAPY OVERVIEW AND APPLICATORS
Krishan Murari
 
Physiology of Chemical Sensation of smell.pdf
Physiology of Chemical Sensation of smell.pdfPhysiology of Chemical Sensation of smell.pdf
Physiology of Chemical Sensation of smell.pdf
MedicoseAcademics
 
KDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologistsKDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologists
د.محمود نجيب
 
micro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdfmicro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdf
Anurag Sharma
 
Gram Stain introduction, principle, Procedure
Gram Stain introduction, principle, ProcedureGram Stain introduction, principle, Procedure
Gram Stain introduction, principle, Procedure
Suraj Goswami
 
How to Give Better Lectures: Some Tips for Doctors
How to Give Better Lectures: Some Tips for DoctorsHow to Give Better Lectures: Some Tips for Doctors
How to Give Better Lectures: Some Tips for Doctors
LanceCatedral
 
Adv. biopharm. APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMS
Adv. biopharm. APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMSAdv. biopharm. APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMS
Adv. biopharm. APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMS
AkankshaAshtankar
 
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdf
ARTIFICIAL INTELLIGENCE IN  HEALTHCARE.pdfARTIFICIAL INTELLIGENCE IN  HEALTHCARE.pdf
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdf
Anujkumaranit
 
A Classical Text Review on Basavarajeeyam
A Classical Text Review on BasavarajeeyamA Classical Text Review on Basavarajeeyam
A Classical Text Review on Basavarajeeyam
Dr. Jyothirmai Paindla
 
Flu Vaccine Alert in Bangalore Karnataka
Flu Vaccine Alert in Bangalore KarnatakaFlu Vaccine Alert in Bangalore Karnataka
Flu Vaccine Alert in Bangalore Karnataka
addon Scans
 
Superficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptxSuperficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptx
Dr. Rabia Inam Gandapore
 
Knee anatomy and clinical tests 2024.pdf
Knee anatomy and clinical tests 2024.pdfKnee anatomy and clinical tests 2024.pdf
Knee anatomy and clinical tests 2024.pdf
vimalpl1234
 
Novas diretrizes da OMS para os cuidados perinatais de mais qualidade
Novas diretrizes da OMS para os cuidados perinatais de mais qualidadeNovas diretrizes da OMS para os cuidados perinatais de mais qualidade
Novas diretrizes da OMS para os cuidados perinatais de mais qualidade
Prof. Marcus Renato de Carvalho
 

Recently uploaded (20)

Dehradun #ℂall #gIRLS Oyo Hotel 9719300533 #ℂall #gIRL in Dehradun
Dehradun #ℂall #gIRLS Oyo Hotel 9719300533 #ℂall #gIRL in DehradunDehradun #ℂall #gIRLS Oyo Hotel 9719300533 #ℂall #gIRL in Dehradun
Dehradun #ℂall #gIRLS Oyo Hotel 9719300533 #ℂall #gIRL in Dehradun
 
Colonic and anorectal physiology with surgical implications
Colonic and anorectal physiology with surgical implicationsColonic and anorectal physiology with surgical implications
Colonic and anorectal physiology with surgical implications
 
Basavarajeeyam - Ayurvedic heritage book of Andhra pradesh
Basavarajeeyam - Ayurvedic heritage book of Andhra pradeshBasavarajeeyam - Ayurvedic heritage book of Andhra pradesh
Basavarajeeyam - Ayurvedic heritage book of Andhra pradesh
 
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
 
Top 10 Best Ayurvedic Kidney Stone Syrups in India
Top 10 Best Ayurvedic Kidney Stone Syrups in IndiaTop 10 Best Ayurvedic Kidney Stone Syrups in India
Top 10 Best Ayurvedic Kidney Stone Syrups in India
 
Pharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptx
Pharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptxPharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptx
Pharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptx
 
Evaluation of antidepressant activity of clitoris ternatea in animals
Evaluation of antidepressant activity of clitoris ternatea in animalsEvaluation of antidepressant activity of clitoris ternatea in animals
Evaluation of antidepressant activity of clitoris ternatea in animals
 
BRACHYTHERAPY OVERVIEW AND APPLICATORS
BRACHYTHERAPY OVERVIEW  AND  APPLICATORSBRACHYTHERAPY OVERVIEW  AND  APPLICATORS
BRACHYTHERAPY OVERVIEW AND APPLICATORS
 
Physiology of Chemical Sensation of smell.pdf
Physiology of Chemical Sensation of smell.pdfPhysiology of Chemical Sensation of smell.pdf
Physiology of Chemical Sensation of smell.pdf
 
KDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologistsKDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologists
 
micro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdfmicro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdf
 
Gram Stain introduction, principle, Procedure
Gram Stain introduction, principle, ProcedureGram Stain introduction, principle, Procedure
Gram Stain introduction, principle, Procedure
 
How to Give Better Lectures: Some Tips for Doctors
How to Give Better Lectures: Some Tips for DoctorsHow to Give Better Lectures: Some Tips for Doctors
How to Give Better Lectures: Some Tips for Doctors
 
Adv. biopharm. APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMS
Adv. biopharm. APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMSAdv. biopharm. APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMS
Adv. biopharm. APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMS
 
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdf
ARTIFICIAL INTELLIGENCE IN  HEALTHCARE.pdfARTIFICIAL INTELLIGENCE IN  HEALTHCARE.pdf
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdf
 
A Classical Text Review on Basavarajeeyam
A Classical Text Review on BasavarajeeyamA Classical Text Review on Basavarajeeyam
A Classical Text Review on Basavarajeeyam
 
Flu Vaccine Alert in Bangalore Karnataka
Flu Vaccine Alert in Bangalore KarnatakaFlu Vaccine Alert in Bangalore Karnataka
Flu Vaccine Alert in Bangalore Karnataka
 
Superficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptxSuperficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptx
 
Knee anatomy and clinical tests 2024.pdf
Knee anatomy and clinical tests 2024.pdfKnee anatomy and clinical tests 2024.pdf
Knee anatomy and clinical tests 2024.pdf
 
Novas diretrizes da OMS para os cuidados perinatais de mais qualidade
Novas diretrizes da OMS para os cuidados perinatais de mais qualidadeNovas diretrizes da OMS para os cuidados perinatais de mais qualidade
Novas diretrizes da OMS para os cuidados perinatais de mais qualidade
 

Argus Patient Screen Tab Training - Katalyst HLS

  • 2. Patient Information: For SR & LIT cases  Enter initials only  Protect Confidentiality box not checked 01/29/17Katalyst Healthcares & Life Sciences 2
  • 3. Patient Information For PMS cases  Enter initials only  Enter patient ID if reported  Protect Confidentiality box not checked 01/29/17Katalyst Healthcares & Life Sciences 3
  • 4. Patient Information (cont)Patient Information (cont)  Enter date of birth. If incomplete type in hyphen for missing information. eg ‘-’ ‘-’ 1994  Patient age: Age and age group will only be calculated automatically if the date of birth and a full event onset date are entered.  If partial onset date has been entered enter the age and age group manually.  Ethnicity: SR - To be entered as locally required CT - Entered if information provided 01/29/17Katalyst Healthcares & Life Sciences 4
  • 5. Other Relevant History:Other Relevant History:  Enter relevant medical history including current medical conditions.  As a general rule, indications of suspect drugs should not be entered as relevant history. However there are exceptions where the condition has happened more than once eg. Transplant.  The indications of co-medications should be entered and coded in the relevant medical history field as they highlight the current condition of the patient. 01/29/17Katalyst Healthcares & Life Sciences 5
  • 6. Other Relevant History (Cont)Other Relevant History (Cont)  The following ‘Condition Type’ are used by Novartis: - Current Condition - Historical Condition - Historical Drug - Drug Reaction History - Family History Leave blank if unknown  Repeat ‘Description’ verbatim term in the Notes field if the Preferred Term is not specific enough. 01/29/17Katalyst Healthcares & Life Sciences 6
  • 7. Medical History Field  Historical drugs can be represented in the medical history field if required.  Select ‘Historical Drug’ as condition type.  The drug name can then be coded against the WHO dictionary.  The Indication for the ‘Historical Drug’ can be entered as well as the reaction if known 01/29/17Katalyst Healthcares & Life Sciences 7
  • 8. ‘Historical Drugs’ Condition type When to Use:  This condition should be used only in the following situations: − Historical drugs that have been highlighted by the reporter as medically relevant to the patient’s status. − Specific historical drugs/therapies highlighted by the Novartis medical safety physician as medically relevant and requiring routine screening. 01/29/17Katalyst Healthcares & Life Sciences 8
  • 9. Definition of a historical drug:  The decision as to whether a medication is historical or not should be based on the following: − If unlikely that the product is still in the body system and there are no biological effects known or suspected in the patient, enter as a ‘Historical Drug’ in the Other Relevant History. − If the drug is still in the body system and there is a suggestion of biological activity (even if the kinetics suggest complete elimination), the product should be entered as a co-medication in the Product tab − If in doubt, consult the PVL. ‘Historical Drugs’ Condition type 01/29/17Katalyst Healthcares & Life Sciences 9
  • 10. Other Relevant History (Cont)Other Relevant History (Cont)  To enter more patient history data click on the Add button  To delete a history record, click on the Delete button  Ongoing checkbox: Not used by Novartis 01/29/17Katalyst Healthcares & Life Sciences 10
  • 11. Laboratory Data:  Relevant tests such as laboratory data, scans, tests and examinations should be captured in the coded field for E2b submissions and also as free texts in the free text Relevant Tests field 01/29/17Katalyst Healthcares & Life Sciences 11
  • 12. Coded Lab Data Field:  Only enter test results that are relevant to the events being reported. The coded field should summarise the essential test results and should only include tests which:  Show abnormalities outside of the normal range relevant to the events being reported.  Disprove a diagnosis or suspected underlying cause for the event  Support or confirm a diagnosis  Show trends, e.g. increasing white blood cell count during an infection. Always include a baseline value if provided followed by the peak and resolution values  Show a normalisation of previously abnormal test results  Do not include tests which:  Show abnormal values that are normal/baseline in the specific patient population under study.  Are not relevant to the events being reported. 01/29/17Katalyst Healthcares & Life Sciences 12
  • 13. Coded Lab Data Field:  Type in the test name as reported and click on ‚Encode‘  Click on units field and select the appropriate units if reported  Enter the Normal range if reported  To enter a test result and click on ‚Add test‘ 01/29/17 Katalyst Healthcares & Life Sciences 13
  • 14. Coded Lab Data Field:  Click on ‚Add Date‘  Enter the date and click on the orange triangle and click on Add 01/29/17 Katalyst Healthcares & Life Sciences 14
  • 15. Coded Lab Data Field:  Enter the result and select Normal, High or low from the drop down list  The Notes field can also be used to display results for investigations which do not have numerical values e.g. ECG and biopsy results. 01/29/17Katalyst Healthcares & Life Sciences 15
  • 16. Relevant Test Field:  In the event that a test can not be coded or captured appropriately in the coded text field, it can be entered as free text in the relevant test field.  Enter date or relevant time point of test in brackets, e.g. (14 Mar 2007) or (10 days post transplant) or (Date unknown)  Enter test specification followed by test result, e.g. Haemoglobin 9.4  Enter test units if reported, e.g. Haemoglobin 9.4 g/dL  If the same test is repeated over a number of days, a normal range should only be entered next to the first entry as shown in the example.  Group similar laboratory tests. Abbreviations can be used if the test is fully defined for the first result or in the case narrative.  Enter repeated tests in date order so that any trend over time can be clearly seen  Example: (Date unknown) AST 20 U/L (normal range 15-30) (Date unknown) AST 150 U/L (Date unknown) AST 40 U/L 01/29/17Katalyst Healthcares & Life Sciences 16
  • 17. Thank YouThank You && QuestionsQuestions 17 Contact: Katalyst Healthcare’s & Life Sciences South Plainfield, NJ, USA 07080. E-Mail: info@KatalystHLS.com

Editor's Notes

  1. Remember to check after entering event onset date that age and age group have been entered. Remember that if you later receive a complete onset date, the age or age group must be deleted for Argus to calculate these fields automatically.
  2. Other relevant history is encoded by MedDRA therefore it is not necessary to enter the verbatim in description as the preferred term populates the field when relevant history is encoded. The red cross is replaced by a green tick to show the field is encoded.